The role of the innate immune system in destruction of pancreatic beta cells in NOD mice and humans with type I diabetes

Journal of Autoimmunity

Volumn 71, Issue , 2016, Pages 26-34

  Tai, Ningwen ^a   Wong, F Susan ^b   Wen, Li ^a  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b CARDIFF UNIVERSITY SCHOOL OF MEDICINE   (United Kingdom)

Author keywords

Adaptive immunity; Innate immunity; Pattern recognition receptors; Type 1 diabetes; cells

Indexed keywords

MYELOID DIFFERENTIATION FACTOR 88; PATTERN RECOGNITION RECEPTOR; TOLL LIKE RECEPTOR 2; TOLL LIKE RECEPTOR 3; TOLL LIKE RECEPTOR 4; TOLL LIKE RECEPTOR 5; TOLL LIKE RECEPTOR 7; TOLL LIKE RECEPTOR 9; TOLL LIKE RECEPTOR;

ADAPTIVE IMMUNITY; AUTOIMMUNITY; CELL DESTRUCTION; DISEASE COURSE; GENE; GENETIC ASSOCIATION; HUMAN; INNATE IMMUNITY; INSULIN DEPENDENT DIABETES MELLITUS; MICROORGANISM; MOUSE; NLRP3 GENE; NONHUMAN; PANCREAS ISLET BETA CELL; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVIEW; SINGLE NUCLEOTIDE POLYMORPHISM; ANIMAL; DIABETES MELLITUS, TYPE 1; IMMUNOLOGY; METABOLISM; NONOBESE DIABETIC MOUSE; PATHOLOGY; SIGNAL TRANSDUCTION;

ADAPTIVE IMMUNITY; ANIMALS; AUTOIMMUNITY; DIABETES MELLITUS, TYPE 1; IMMUNITY, INNATE; INSULIN-SECRETING CELLS; MICE, INBRED NOD; RECEPTORS, PATTERN RECOGNITION; SIGNAL TRANSDUCTION; TOLL-LIKE RECEPTORS;

EID: 84961843538     PISSN: 08968411     EISSN: 10959157     Source Type: Journal    
DOI: 10.1016/j.jaut.2016.03.006     Document Type: Review

References (116)

1. Bluestone J.A., Herold K., Eisenbarth G. Genetics, pathogenesis and clinical interventions in type 1 diabetes. Nature 2010, 464:1293-1300.
2. Wallberg M., Cooke A. Immune mechanisms in type 1 diabetes. Trends Immunol. 2013, 34:583-591.
3. Aronson R., Gottlieb P.A., Christiansen J.S., Donner T.W., Bosi E., Bode B.W., et al. Low-dose otelixizumab anti-CD3 monoclonal antibody DEFEND-1 study: results of the randomized phase III study in recent-onset human type 1 diabetes. Diabetes Care 2014, 37:2746-2754.
4. Lehuen A., Diana J., Zaccone P., Cooke A. Immune cell crosstalk in type 1 diabetes. Nat. Rev. Immunol. 2010, 10:501-513.
5. Moran A., Bundy B., Becker D.J., DiMeglio L.A., Gitelman S.E., Goland R., et al. Interleukin-1 antagonism in type 1 diabetes of recent onset: two multicentre, randomised, double-blind, placebo-controlled trials. Lancet 2013, 381:1905-1915.
6. Orban T., Bundy B., Becker D.J., DiMeglio L.A., Gitelman S.E., Goland R., et al. Co-stimulation modulation with abatacept in patients with recent-onset type 1 diabetes: a randomised, double-blind, placebo-controlled trial. Lancet 2011, 378:412-419.
7. Pescovitz M.D., Greenbaum C.J., Krause-Steinrauf H., Becker D.J., Gitelman S.E., Goland R., et al. Rituximab, B-lymphocyte depletion, and preservation of beta-cell function. N. Engl. J. Med. 2009, 361:2143-2152.
8. Sherry N., Hagopian W., Ludvigsson J., Jain S.M., Wahlen J., Ferry R.J., et al. Teplizumab for treatment of type 1 diabetes (Protege study): 1-year results from a randomised, placebo-controlled trial. Lancet 2011, 378:487-497.
9. Vudattu N.K., Herold K.C. Treatment of new onset type 1 diabetes with teplizumab: successes and pitfalls in development. Expert Opin. Biol. Ther. 2014, 14:377-385.
10. Diana J., Gahzarian L., Simoni Y., Lehuen A. Innate immunity in type 1 diabetes. Discov. Med. 2011, 11:513-520.
11. Tlaskalova-Hogenova H., Stepankova R., Kozakova H., Hudcovic T., Vannucci L., Tuckova L., et al. The role of gut microbiota (commensal bacteria) and the mucosal barrier in the pathogenesis of inflammatory and autoimmune diseases and cancer: contribution of germ-free and gnotobiotic animal models of human diseases. Cell Mol. Immunol. 2011, 8:110-120.
12. Wen L., Ley R.E., Volchkov P.Y., Stranges P.B., Avanesyan L., Stonebraker A.C., et al. Innate immunity and intestinal microbiota in the development of Type 1 diabetes. Nature 2008, 455:1109-1113.
13. Chu H., Mazmanian S.K. Innate immune recognition of the microbiota promotes host-microbial symbiosis. Nat. Immunol. 2013, 14:668-675.
14. Kamada N., Seo S.U., Chen G.Y., Nunez G. Role of the gut microbiota in immunity and inflammatory disease. Nat. Rev. Immunol. 2013, 13:321-335.
15. Round J.L., Mazmanian S.K. The gut microbiota shapes intestinal immune responses during health and disease. Nat. Rev. Immunol. 2009, 9:313-323.
16. Wu H.J., Wu E. The role of gut microbiota in immune homeostasis and autoimmunity. Gut Microbes 2012, 3:4-14.
17. Medzhitov R., Janeway C. Innate immunity. N. Engl. J. Med. 2000, 343:338-344.
18. Medzhitov R. Recognition of microorganisms and activation of the immune response. Nature 2007, 449:819-826.
19. Brubaker S.W., Bonham K.S., Zanoni I., Kagan J.C. Innate immune pattern recognition: a cell biological perspective. Annu. Rev. Immunol. 2015, 33:257-290.
20. Kawai T., Akira S. The roles of TLRs, RLRs and NLRs in pathogen recognition. Int. Immunol. 2009, 21:317-337.
21. Kuchroo V.K., Ohashi P.S., Sartor R.B., Vinuesa C.G. Dysregulation of immune homeostasis in autoimmune diseases. Nat. Med. 2012, 18:42-47.
22. Kawasaki T., Kawai T. Toll-like receptor signaling pathways. Front. Immunol. 2014, 5:461.
23. Akira S., Uematsu S., Takeuchi O. Pathogen recognition and innate immunity. Cell 2006, 124:783-801.
24. Kawai T., Akira S. The role of pattern-recognition receptors in innate immunity: update on Toll-like receptors. Nat. Immunol. 2010, 11:373-384.
25. O'Neill L.A., Golenbock D., Bowie A.G. The history of Toll-like receptors - redefining innate immunity. Nat. Rev. Immunol. 2013, 13:453-460.
26. Zipris D. Innate immunity and its role in type 1 diabetes. Curr. Opin. Endocrinol. Diabetes Obes. 2008, 15:326-331.
27. Roesch L.F., Lorca G.L., Casella G., Giongo A., Naranjo A., Pionzio A.M., et al. Culture-independent identification of gut bacteria correlated with the onset of diabetes in a rat model. ISME J. 2009, 3:536-548.
28. Gulden E., Wen L. Toll-like receptor activation in immunity vs. Tolerance in autoimmune diabetes. Front. Immunol. 2014, 5:119.
29. Takeuchi O., Akira S. Pattern recognition receptors and inflammation. Cell 2010, 140:805-820.
30. Liu Y., Yin H., Zhao M., Lu Q. TLR2 and TLR4 in autoimmune diseases: a comprehensive review. Clin. Rev. Allergy Immunol. 2014, 47:136-147.
31. Jin M.S., Kim S.E., Heo J.Y., Lee M.E., Kim H.M., Paik S.G., et al. Crystal structure of the TLR1-TLR2 heterodimer induced by binding of a tri-acylated lipopeptide. Cell 2007, 130:1071-1082.
32. Oliveira-Nascimento L., Massari P., Wetzler L.M. The role of TLR2 in infection and immunity. Front. Immunol. 2012, 3:79.
33. Kim H.S., Han M.S., Chung K.W., Kim S., Kim E., Kim M.J., et al. Toll-like receptor 2 senses beta-cell death and contributes to the initiation of autoimmune diabetes. Immunity 2007, 27:321-333.
34. Lee M.S., Kim D.H., Lee J.C., Kim S., Kim H.S. Role of TLR2 in the pathogenesis of autoimmune diabetes and its therapeutic implication. Diabetes Metab. Res. Rev. 2011, 27:797-801.
35. Burrows M.P., Volchkov P., Kobayashi K.S., Chervonsky A.V. Microbiota regulates type 1 diabetes through Toll-like receptors. Proc. Natl. Acad. Sci. U. S. A. 2015, 112:9973-9977.
36. Filippi C.M., Ehrhardt K., Estes E.A., Larsson P., Oldham J.E., von Herrath M.G. TLR2 signaling improves immunoregulation to prevent type 1 diabetes. Eur. J. Immunol. 2011, 41:1399-1409.
37. Kim D.H., Lee J.C., Kim S., Oh S.H., Lee M.K., Kim K.W., et al. Inhibition of autoimmune diabetes by TLR2 tolerance. J. Immunol. 2011, 187:5211-5220.
38. Liu H., Komai-Koma M., Xu D., Liew F.Y. Toll-like receptor 2 signaling modulates the functions of CD4+ CD25+ regulatory T cells. Proc. Natl. Acad. Sci. U. S. A. 2006, 103:7048-7053.
39. Sutmuller R.P., den Brok M.H., Kramer M., Bennink E.J., Toonen L.W., Kullberg B.J., et al. Toll-like receptor 2 controls expansion and function of regulatory T cells. J. Clin. Invest 2006, 116:485-494.
40. Karumuthil-Melethil S., Perez N., Li R., Vasu C. Induction of innate immune response through TLR2 and dectin 1 prevents type 1 diabetes. J. Immunol. 2008, 181:8323-8334.
41. Karumuthil-Melethil S., Sofi M.H., Gudi R., Johnson B.M., Perez N., Vasu C. TLR2- and Dectin 1-associated innate immune response modulates T-cell response to pancreatic beta-cell antigen and prevents type 1 diabetes. Diabetes 2015, 64:1341-1357.
42. Alexopoulou L., Holt A.C., Medzhitov R., Flavell R.A. Recognition of double-stranded RNA and activation of NF-kappaB by Toll-like receptor 3. Nature 2001, 413:732-738.
43. Assmann T.S., Brondani Lde A., Boucas A.P., Canani L.H., Crispim D. Toll-like receptor 3 (TLR3) and the development of type 1 diabetes mellitus. Arch. Endocrinol. Metab. 2015, 59:4-12.
44. Dar A.A., Patil R.S., Chiplunkar S.V. Insights into the relationship between toll like receptors and gamma Delta T cell responses. Front. Immunol. 2014, 5:366.
45. Wesch D., Beetz S., Oberg H.H., Marget M., Krengel K., Kabelitz D. Direct costimulatory effect of TLR3 ligand poly(I: C) on human gamma delta T lymphocytes. J. Immunol. 2006, 176:1348-1354.
46. Jiang Z., Mak T.W., Sen G., Li X. Toll-like receptor 3-mediated activation of NF-kappaB and IRF3 diverges at Toll-IL-1 receptor domain-containing adapter inducing IFN-beta. Proc. Natl. Acad. Sci. U. S. A. 2004, 101:3533-3538.
47. Serreze D.V., Hamaguchi K., Leiter E.H. Immunostimulation circumvents diabetes in NOD/Lt mice. J. Autoimmun. 1989, 2:759-776.
48. Sobel D.O., Newsome J., Ewel C.H., Bellanti J.A., Abbassi V., Creswell K., et al. Poly I: C induces development of diabetes mellitus in BB rat. Diabetes 1992, 41:515-520.
49. Sobel D.O., Goyal D., Ahvazi B., Yoon J.W., Chung Y.H., Bagg A., et al. Low dose poly I: C prevents diabetes in the diabetes prone BB rat. J. Autoimmun. 1998, 11:343-352.
50. Blankenhorn E.P., Cort L., Greiner D.L., Guberski D.L., Mordes J.P. Virus-induced autoimmune diabetes in the LEW.1WR1 rat requires Iddm14 and a genetic locus proximal to the major histocompatibility complex. Diabetes 2009, 58:2930-2938.
51. Wen L., Peng J., Li Z., Wong F.S. The effect of innate immunity on autoimmune diabetes and the expression of Toll-like receptors on pancreatic islets. J. Immunol. 2004, 172:3173-3180.
52. Hober D., Sauter P. Pathogenesis of type 1 diabetes mellitus: interplay between enterovirus and host. Nat. Rev. Endocrinol. 2010, 6:279-289.
53. Coppieters K.T., Boettler T., von Herrath M. Virus infections in type 1 diabetes. Cold Spring Harb. Perspect. Med. 2012, 2:a007682.
54. Laitinen O.H., Honkanen H., Pakkanen O., Oikarinen S., Hankaniemi M.M., Huhtala H., et al. Coxsackievirus B1 is associated with induction of beta-cell autoimmunity that portends type 1 diabetes. Diabetes 2014, 63:446-455.
55. Oikarinen S., Tauriainen S., Hober D., Lucas B., Vazeou A., Sioofy-Khojine A., et al. Virus antibody survey in different European populations indicates risk association between coxsackievirus B1 and type 1 diabetes. Diabetes 2014, 63:655-662.
56. Aida K., Nishida Y., Tanaka S., Maruyama T., Shimada A., Awata T., et al. RIG-I- and MDA5-initiated innate immunity linked with adaptive immunity accelerates beta-cell death in fulminant type 1 diabetes. Diabetes 2011, 60:884-889.
57. Le Bon A., Durand V., Kamphuis E., Thompson C., Bulfone-Paus S., Rossmann C., et al. Direct stimulation of T cells by type I IFN enhances the CD8+ T cell response during cross-priming. J. Immunol. 2006, 176:4682-4689.
58. Hultcrantz M., Huhn M.H., Wolf M., Olsson A., Jacobson S., Williams B.R., et al. Interferons induce an antiviral state in human pancreatic islet cells. Virology 2007, 367:92-101.
59. Ylipaasto P., Kutlu B., Rasilainen S., Rasschaert J., Salmela K., Teerijoki H., et al. Global profiling of coxsackievirus- and cytokine-induced gene expression in human pancreatic islets. Diabetologia 2005, 48:1510-1522.
60. Pirie F.J., Pegoraro R., Motala A.A., Rauff S., Rom L., Govender T., et al. Toll-like receptor 3 gene polymorphisms in South African Blacks with type 1 diabetes. Tissue Antigens 2005, 66:125-130.
61. Eleftherohorinou H., Wright V., Hoggart C., Hartikainen A.L., Jarvelin M.R., Balding D., et al. Pathway analysis of GWAS provides new insights into genetic susceptibility to 3 inflammatory diseases. PLoS One 2009, 4:e8068.
62. Assmann T.S., Brondani Lde A., Bauer A.C., Canani L.H., Crispim D. Polymorphisms in the TLR3 gene are associated with risk for type 1 diabetes mellitus. Eur. J. Endocrinol. 2014, 170:519-527.
63. Fichna M., Zurawek M., Fichna P., Januszkiewicz-Lewandowska D., Ruchala M., Nowak J. Polymorphisms of the toll-like Receptor-3 gene in autoimmune adrenal failure and type 1 diabetes in polish patients. Arch. Immunol. Ther. Exp. Warsz. 2016, 64:83-87.
64. Witso E., Cinek O., Tapia G., Brorsson C.A., Stene L.C., Gjessing H.K., et al. Genetic determinants of enterovirus infections: polymorphisms in type 1 diabetes and innate immune genes in the MIDIA study. Viral Immunol. 2015, 28:556-563.
65. Wong F.S., Hu C., Zhang L., Du W., Alexopoulou L., Flavell R.A., et al. The role of Toll-like receptors 3 and 9 in the development of autoimmune diabetes in NOD mice. Ann. N. Y. Acad. Sci. 2008, 1150:146-148.
66. Lang K.S., Recher M., Junt T., Navarini A.A., Harris N.L., Freigang S., et al. Toll-like receptor engagement converts T-cell autoreactivity into overt autoimmune disease. Nat. Med. 2005, 11:138-145.
67. McCall K.D., Thuma J.R., Courreges M.C., Benencia F., James C.B., Malgor R., et al. Toll-like receptor 3 is critical for coxsackievirus B4-induced type 1 diabetes in female NOD mice. Endocrinology 2015, 156:453-461.
68. Lee A.S., Ghoreishi M., Cheng W.K., Chang T.Y., Zhang Y.Q., Dutz J.P. Toll-like receptor 7 stimulation promotes autoimmune diabetes in the NOD mouse. Diabetologia 2011, 54:1407-1416.
69. Pane J.A., Webster N.L., Coulson B.S. Rotavirus activates lymphocytes from non-obese diabetic mice by triggering toll-like receptor 7 signaling and interferon production in plasmacytoid dendritic cells. PLoS Pathog. 2014, 10:e1003998.
70. Devaraj S., Dasu M.R., Rockwood J., Winter W., Griffen S.C., Jialal I. Increased toll-like receptor (TLR) 2 and TLR4 expression in monocytes from patients with type 1 diabetes: further evidence of a proinflammatory state. J. Clin. Endocrinol. Metab. 2008, 93:578-583.
71. Mohammad M.K., Morran M., Slotterbeck B., Leaman D.W., Sun Y., Grafenstein H., et al. Dysregulated Toll-like receptor expression and signaling in bone marrow-derived macrophages at the onset of diabetes in the non-obese diabetic mouse. Int. Immunol. 2006, 18:1101-1113.
72. Garay-Malpartida H.M., Mourao R.F., Mantovani M., Santos I.A., Sogayar M.C., Goldberg A.C. Toll-like receptor 4 (TLR4) expression in human and murine pancreatic beta-cells affects cell viability and insulin homeostasis. BMC Immunol. 2011, 12:18.
73. Li M., Song L., Gao X., Chang W., Qin X. Toll-like receptor 4 on islet beta cells senses expression changes in high-mobility group box 1 and contributes to the initiation of type 1 diabetes. Exp. Mol. Med. 2012, 44:260-267.
74. Bednar K.J., Tsukamoto H., Kachapati K., Ohta S., Wu Y., Katz J.D., et al. Reversal of new-onset type 1 diabetes with an agonistic TLR4/MD-2 monoclonal antibody. Diabetes 2015, 64:3614-3626.
75. Gulden E., Ihira M., Ohashi A., Reinbeck A.L., Freudenberg M.A., Kolb H., et al. Toll-like receptor 4 deficiency accelerates the development of insulin-deficient diabetes in non-obese diabetic mice. PLoS One 2013, 8:e75385.
76. Tian J., Zekzer D., Hanssen L., Lu Y., Olcott A., Kaufman D.L. Lipopolysaccharide-activated B cells down-regulate Th1 immunity and prevent autoimmune diabetes in nonobese diabetic mice. J. Immunol. 2001, 167:1081-1089.
77. Uematsu S., Fujimoto K., Jang M.H., Yang B.G., Jung Y.J., Nishiyama M., et al. Regulation of humoral and cellular gut immunity by lamina propria dendritic cells expressing Toll-like receptor 5. Nat. Immunol. 2008, 9:769-776.
78. Choi Y.J., Im E., Chung H.K., Pothoulakis C., Rhee S.H. TRIF mediates Toll-like receptor 5-induced signaling in intestinal epithelial cells. J. Biol. Chem. 2010, 285:37570-37578.
79. Vijay-Kumar M., Aitken J.D., Carvalho F.A., Cullender T.C., Mwangi S., Srinivasan S., et al. Metabolic syndrome and altered gut microbiota in mice lacking Toll-like receptor 5. Science 2010, 328:228-231.
80. Weile C., Josefsen K., Buschard K. Glucose activation of islets of Langerhans up-regulates Toll-like receptor 5: possible mechanism of protection. Clin. Exp. Immunol. 2011, 166:251-257.
81. Applequist S.E., Wallin R.P., Ljunggren H.G. Variable expression of Toll-like receptor in murine innate and adaptive immune cell lines. Int. Immunol. 2002, 14:1065-1074.
82. Wu O., Chen G.P., Chen H., Li X.P., Xu J.H., Zhao S.S., et al. The expressions of Toll-like receptor 9 and T-bet in circulating B and T cells in newly diagnosed, untreated systemic lupus erythematosus and correlations with disease activity and laboratory data in a Chinese population. Immunobiology 2009, 214:392-402.
83. Blasius A.L., Beutler B. Intracellular toll-like receptors. Immunity 2010, 32:305-315.
84. Hammond T., Lee S., Watson M.W., Flexman J.P., Cheng W., Fernandez S., et al. Toll-like receptor (TLR) expression on CD4+ and CD8+ T-cells in patients chronically infected with hepatitis C virus. Cell Immunol. 2010, 264:150-155.
85. Agudo J., Ruzo A., Tung N., Salmon H., Leboeuf M., Hashimoto D., et al. The miR-126-VEGFR2 axis controls the innate response to pathogen-associated nucleic acids. Nat. Immunol. 2014, 15:54-62.
86. Kato H., Sato S., Yoneyama M., Yamamoto M., Uematsu S., Matsui K., et al. Cell type-specific involvement of RIG-I in antiviral response. Immunity 2005, 23:19-28.
87. Tai N., Wong F.S., Wen L. TLR9 deficiency promotes CD73 expression in T cells and diabetes protection in nonobese diabetic mice. J. Immunol. 2013, 191:2926-2937.
88. Zhang Y., Lee A.S., Shameli A., Geng X., Finegood D., Santamaria P., et al. TLR9 blockade inhibits activation of diabetogenic CD8+ T cells and delays autoimmune diabetes. J. Immunol. 2010, 184:5645-5653.
89. Kayserova J., Vcelakova J., Stechova K., Dudkova E., Hromadkova H., Sumnik Z., et al. Decreased dendritic cell numbers but increased TLR9-mediated interferon-alpha production in first degree relatives of type 1 diabetes patients. Clin. Immunol. 2014, 153:49-55.
90. Wong F.S., Wen L. IFN-alpha can both protect against and promote the development of type 1 diabetes. Ann. N. Y. Acad. Sci. 2008, 1150:187-189.
91. Gianchecchi E., Crino A., Giorda E., Luciano R., Perri V., Russo A.L., et al. Altered B cell homeostasis and toll-like receptor 9-driven response in type 1 diabetes carriers of the C1858T PTPN22 allelic variant: implications in the disease pathogenesis. PLoS One 2014, 9:e110755.
92. Hooper L.V., Littman D.R., Macpherson A.J. Interactions between the microbiota and the immune system. Science 2012, 336:1268-1273.
93. Brandl K., Plitas G., Schnabl B., DeMatteo R.P., Pamer E.G. MyD88-mediated signals induce the bactericidal lectin RegIII gamma and protect mice against intestinal Listeria monocytogenes infection. J. Exp. Med. 2007, 204:1891-1900.
94. Vaishnava S., Behrendt C.L., Ismail A.S., Eckmann L., Hooper L.V. Paneth cells directly sense gut commensals and maintain homeostasis at the intestinal host-microbial interface. Proc. Natl. Acad. Sci. U. S. A. 2008, 105:20858-20863.
95. Perry A.K., Chen G., Zheng D., Tang H., Cheng G. The host type I interferon response to viral and bacterial infections. Cell Res. 2005, 15:407-422.
96. Longhi M.P., Trumpfheller C., Idoyaga J., Caskey M., Matos I., Kluger C., et al. Dendritic cells require a systemic type I interferon response to mature and induce CD4+ Th1 immunity with poly IC as adjuvant. J. Exp. Med. 2009, 206:1589-1602.
97. Sporri R., Reis e Sousa C. Inflammatory mediators are insufficient for full dendritic cell activation and promote expansion of CD4+ T cell populations lacking helper function. Nat. Immunol. 2005, 6:163-170.
98. Sun C., Zhi D., Shen S., Luo F., Sanjeevi C.B. SNPs in the exons of Toll-like receptors are associated with susceptibility to type 1 diabetes in Chinese population. Hum. Immunol. 2014, 75:1084-1088.
99. Cooper J.D., Walker N.M., Smyth D.J., Downes K., Healy B.C., Todd J.A., et al. Follow-up of 1715 SNPs from the wellcome trust case control Consortium genome-wide association study in type I diabetes families. Genes Immun. 2009, 10(Suppl 1):S85-S94.
100. Claes A.K., Zhou J.Y., Philpott D.J. NOD-Like receptors: guardians of intestinal mucosal barriers. Physiol. (Bethesda) 2015, 30:241-250.
101. Geddes K., Magalhaes J.G., Girardin S.E. Unleashing the therapeutic potential of NOD-like receptors. Nat. Rev. Drug Discov. 2009, 8:465-479.
102. Newton K., Dixit V.M. Signaling in innate immunity and inflammation. Cold Spring Harb. Perspect. Biol. 2012, 4.
103. Berrington W.R., Iyer R., Wells R.D., Smith K.D., Skerrett S.J., Hawn T.R. NOD1 and NOD2 regulation of pulmonary innate immunity to Legionella pneumophila. Eur. J. Immunol. 2010, 40:3519-3527.
104. Hasegawa M., Yamazaki T., Kamada N., Tawaratsumida K., Kim Y.G., Nunez G., et al. Nucleotide-binding oligomerization domain 1 mediates recognition of Clostridium difficile and induces neutrophil recruitment and protection against the pathogen. J. Immunol. 2011, 186:4872-4880.
105. Werts C., le Bourhis L., Liu J., Magalhaes J.G., Carneiro L.A., Fritz J.H., et al. Nod1 and Nod2 induce CCL5/RANTES through the NF-kappaB pathway. Eur. J. Immunol. 2007, 37:2499-2508.
106. Latz E., Xiao T.S., Stutz A. Activation and regulation of the inflammasomes. Nat. Rev. Immunol. 2013, 13:397-411.
107. McCoy A.J., Koizumi Y., Higa N., Suzuki T. Differential regulation of caspase-1 activation via NLRP3/NLRC4 inflammasomes mediated by aerolysin and type III secretion system during Aeromonas veronii infection. J. Immunol. 2010, 185:7077-7084.
108. Schroder K., Zhou R., Tschopp J. The NLRP3 inflammasome: a sensor for metabolic danger?. Science 2010, 327:296-300.
109. Gris D., Ye Z., Iocca H.A., Wen H., Craven R.R., Gris P., et al. NLRP3 plays a critical role in the development of experimental autoimmune encephalomyelitis by mediating Th1 and Th17 responses. J. Immunol. 2010, 185:974-981.
110. Kolly L., Karababa M., Joosten L.A., Narayan S., Salvi R., Petrilli V., et al. Inflammatory role of ASC in antigen-induced arthritis is independent of caspase-1, NALP-3, and IPAF. J. Immunol. 2009, 183:4003-4012.
111. Schott W.H., Haskell B.D., Tse H.M., Milton M.J., Piganelli J.D., Choisy-Rossi C.M., et al. Caspase-1 is not required for type 1 diabetes in the NOD mouse. Diabetes 2004, 53:99-104.
112. Wen L., Green E.A., Stratmann T., Panosa A., Gomis R., Eynon E.E., et al. In vivo diabetogenic action of CD4+ T lymphocytes requires Fas expression and is independent of IL-1 and IL-18. Eur. J. Immunol. 2011, 41:1344-1351.
113. Hu C., Ding H., Li Y., Pearson J.A., Zhang X., Flavell R.A., et al. NLRP3 deficiency protects from type 1 diabetes through the regulation of chemotaxis into the pancreatic islets. Proc. Natl. Acad. Sci. U. S. A. 2015, 112:11318-11323.
114. Pontillo A., Brandao L., Guimaraes R., Segat L., Araujo J., Crovella S. Two SNPs in NLRP3 gene are involved in the predisposition to type-1 diabetes and celiac disease in a pediatric population from northeast Brazil. Autoimmunity 2010, 43:583-589.
115. Brooks-Worrell B., Palmer J.P. Prevention versus intervention of type 1 diabetes. Clin. Immunol. 2013, 149:332-338.
116. Herold K.C., Vignali D.A., Cooke A., Bluestone J.A. Type 1 diabetes: translating mechanistic observations into effective clinical outcomes. Nat. Rev. Immunol. 2013, 13:243-a256.